0
Skip to Content
Rejuvenate Bio
Home
Team
Advisory Board
Investors
Partners
Our Science
Pipeline
MVD Trial 2020
MVD Trial 2026
Press Releases
In the News
Contact Us
Invest in Rejuvenate
Rejuvenate Bio
Home
Team
Advisory Board
Investors
Partners
Our Science
Pipeline
MVD Trial 2020
MVD Trial 2026
Press Releases
In the News
Contact Us
Invest in Rejuvenate
Home
Folder: About Us
Back
Team
Advisory Board
Investors
Partners
Our Science
Pipeline
Folder: Trials
Back
MVD Trial 2020
MVD Trial 2026
Folder: Press
Back
Press Releases
In the News
Contact Us
Invest in Rejuvenate

Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy

Oct 9
Written by Noah Davidsohn
Noah Davidsohn
Previous
Previous

Rejuvenate Bio Announces Partnership with Leading Animal Health Company to Develop Gene Therapy for Canine Osteoarthritis
Next
Next

New Preclinical Research Evaluating Cellular Reprogramming for Age Reversal
Rejuvenate_Logo_PNG_Blue.png
 

Home Page

Our Science

Pipeline

Press Releases

In the News

Terms & Conditions

Team

Careers

Contact Us